CNS

UCB has established a leading platform in epilepsy. A group of small molecule drugs is being developed to treat this condition: Keppra® (levetiracetam), brivaracetam and VIMPAT® (lacosamide). A growing portfolio of projects has been established in neurological disorders with a particular focus on Parkinson’s disease, (rotigotine patch, Neupro®), multiple sclerosis (CDP323), fibromyalgia, (lacosamide, rotigotine and Xyrem®), restless legs syndrome (rotigotine), and pain experienced in diabetic neuropathy, migraine and osteoarthritis.